Clinical Trials Logo

FMF clinical trials

View clinical trials related to FMF.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06336733 Not yet recruiting - FMF Clinical Trials

Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy

KIN-ATTACK-FMF
Start date: March 2024
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy on clinical symptoms in case of FMF attack among FMF patients resistant to Colchicine of - on demand anakinra treatment (100 mg/d from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) associated with daily colchicine. - compared to analgesic associated with daily colchicine in patients refusing continuous anti-IL-1 treatment.

NCT ID: NCT06047938 Not yet recruiting - FMF Clinical Trials

FMF and Atheroscelerosis

Start date: December 15, 2023
Phase:
Study type: Observational

The aim of this study is to search for subclinical atherosclerosis in children diagnosed as FMF in Assiut University children's Hospital, and to correlate the risk to develop atherosclerosis to the different characters and genetic variants of FMF.

NCT ID: NCT05292768 Not yet recruiting - FMF Clinical Trials

Are Mast Cells Involved in Autoinflammatory Diseases

INFLAMAST
Start date: March 2022
Phase:
Study type: Observational

Autoinflammatory diseases (AID) are caused by innate immunity dysregulation. AID pathophysiology is only partly understood, especially in the case of unclassified AID. Mast cells (MC) are innate immune cells associated with a spectrum of disease between systemic mastocytosis and mast cell activation syndrome. The implication of MC has been shown in cryopyrin associated periodic syndrome (CAPS).Our aim is to evaluate the involvement of MC in AID by assessing clinical and biological signs of MC activation and studying cutaneous and digestive biopsies.